Innophos (NASDAQ:IPHS) Stock Rating Upgraded by ValuEngine

Innophos (NASDAQ:IPHS) was upgraded by ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued to investors on Tuesday, ValuEngine reports.

A number of other brokerages have also weighed in on IPHS. Zacks Investment Research upgraded shares of Innophos from a “sell” rating to a “hold” rating in a research note on Wednesday, January 1st. BidaskClub cut Innophos from a “sell” rating to a “strong sell” rating in a report on Saturday, January 11th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and one has assigned a buy rating to the company’s stock. Innophos currently has a consensus rating of “Hold” and a consensus price target of $36.00.

IPHS stock traded up $0.01 during midday trading on Tuesday, hitting $31.94. The company’s stock had a trading volume of 1,313 shares, compared to its average volume of 148,473. The company has a market cap of $628.73 million, a PE ratio of 14.01 and a beta of 1.44. Innophos has a 12 month low of $23.85 and a 12 month high of $37.53. The company has a current ratio of 2.94, a quick ratio of 1.48 and a debt-to-equity ratio of 1.01. The firm’s 50-day moving average is $31.92 and its 200-day moving average is $30.52.

Innophos (NASDAQ:IPHS) last issued its earnings results on Wednesday, November 6th. The specialty chemicals company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.55 by ($0.10). The business had revenue of $189.00 million for the quarter, compared to analysts’ expectations of $185.55 million. Innophos had a net margin of 2.82% and a return on equity of 11.56%. The business’s revenue for the quarter was down 4.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.58 earnings per share. Analysts expect that Innophos will post 2.05 earnings per share for the current year.

In other Innophos news, Director John M. Steitz sold 12,625 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $31.86, for a total transaction of $402,232.50. Following the completion of the sale, the director now directly owns 18,103 shares in the company, valued at approximately $576,761.58. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 2.50% of the company’s stock.

A number of hedge funds have recently made changes to their positions in IPHS. Versant Capital Management Inc boosted its stake in shares of Innophos by 55.9% during the 3rd quarter. Versant Capital Management Inc now owns 1,037 shares of the specialty chemicals company’s stock worth $33,000 after acquiring an additional 372 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in Innophos by 471.9% in the 3rd quarter. Tower Research Capital LLC TRC now owns 1,384 shares of the specialty chemicals company’s stock worth $45,000 after purchasing an additional 1,142 shares during the period. Meeder Asset Management Inc. raised its holdings in Innophos by 470.0% in the 3rd quarter. Meeder Asset Management Inc. now owns 1,499 shares of the specialty chemicals company’s stock worth $49,000 after purchasing an additional 1,236 shares during the period. Bank of Montreal Can lifted its position in Innophos by 169.7% during the second quarter. Bank of Montreal Can now owns 2,799 shares of the specialty chemicals company’s stock valued at $80,000 after purchasing an additional 1,761 shares in the last quarter. Finally, Quadrant Capital Group LLC grew its holdings in Innophos by 303.0% during the third quarter. Quadrant Capital Group LLC now owns 3,087 shares of the specialty chemicals company’s stock valued at $98,000 after purchasing an additional 2,321 shares during the period. 92.38% of the stock is owned by institutional investors and hedge funds.

About Innophos

Innophos Holdings, Inc, together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. It operates through three segments: Food, Health and Nutrition; Industrial Specialties; and Other. The company's specialty ingredients include specialty phosphate salts and specialty phosphoric acids, as well as other mineral, enzyme, and botanical based specialty ingredients that are used as flavor enhancers in beverages; electrolytes in sports drinks; texture modifiers in cheeses; leavening agents in baked goods; calcium and phosphorus fortification in food and beverages; moisture and color retention in seafood, poultry, and meat; excipients in vitamins, minerals, nutritional supplements, and pharmaceuticals; and abrasives in toothpaste.

See Also: Support Level

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Innophos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos and related companies with MarketBeat.com's FREE daily email newsletter.